Tamoxifen News and Research

RSS

Tamoxifen is a drug used to treat certain types of breast cancer in women and men. It is also used to prevent breast cancer in women who have had ductal carcinoma in situ (abnormal cells in the ducts of the breast) and in women who are at a high risk of developing breast cancer. Tamoxifen is also being studied in the treatment of other types of cancer. It blocks the effects of the hormone estrogen in the breast. Tamoxifen is a type of antiestrogen. Also called tamoxifen citrate.

New host target identified to block hepatitis E virus

Hepatitis E virus (HEV) is a major cause of acute viral hepatitis, yet antiviral treatment remains largely limited to the off-label use of ribavirin. Ribavirin can cause substantial toxicity, is contraindicated during pregnancy and does not reliably benefit every patient.

29 Oct 2026

Exhausted T cells can escape tumors and confer long-lasting immunity to cancer in mice

As the immune system battles cancer, chronic stimulation gradually drives T cells to a state of exhaustion.

18 Aug 2026

Gut microbes emerge as potential players in estrogen-driven cancers

A new review maps how the endocrine-microbiome axis expands the estrobolome concept, showing that gut microbes may alter estrogen recycling, produce hormone-like metabolites, and shape inflammation and tissue environments in hormone-driven cancers. Human evidence remains mostly associative, so the authors call for causal models, longitudinal multi-omics, multi-kingdom profiling, and sex-stratified studies before microbiome-guided cancer strategies enter routine care.

25 Jun 2026

Could GLP-1 drugs help prevent breast cancer? New study points to a possible link

A large retrospective cohort study of 111,646 overweight or obese women found that GLP-1 agonist exposure was associated with lower breast cancer incidence. After propensity-score matching, GLP-1 exposure was linked to nearly 30% lower odds of breast cancer, but the authors stress that randomized trials are needed before these drugs can be considered for prevention.

3 Jun 2026

GLP-1 medications linked to lower breast cancer risk in women

A retrospective analysis of more than 110,000 women between the ages of 45 and 80 found that those who took GLP-1 medications were about 30 percent less likely to develop breast cancer than those who did not take GLP-1 medications, according to research presented today at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 10506) by Elizabeth McDonald, MD, PhD, a professor of Radiology in the University of Pennsylvania Perelman School of Medicine and a practicing breast radiologist at Penn's Abramson Cancer Center.

2 Jun 2026

Study identifies breakthrough drug combination for early-stage Peyronie’s

Combining two widely prescribed drug classes could provide the first effective treatment for early-stage Peyronie's disease, according to a new study published in The Journal of Sexual Medicine.

15 May 2026

Researchers leverage tamoxifen's active metabolite to improve breast cancer prevention

Low doses of the investigational medicinal product endoxifen reduce breast density to the same extent as the standard treatment tamoxifen, but without causing such troublesome side effects. This is shown by a new study from Karolinska Institutet published in the Journal of the National Cancer Institute. The results may have implications for future preventive treatment of breast cancer.

4 May 2026

Clinical trial tests laser therapy for vaginal dryness in breast cancer survivors

The Alliance for Clinical Trials in Oncology is now enrolling patients into a clinical trial aimed at helping women recover from the vaginal side effects of breast cancer treatment.

13 Apr 2026

Next-generation oral SERD therapy lowers the risk of breast cancer recurrence

In an international study led by UCLA, researchers have shown that giredestrant, a next-generation oral selective estrogen receptor antagonist and degrader (SERD), when given as an adjuvant therapy for early-stage (1-3) hormone receptor (HR)-positive, HER2-negative breast cancer, significantly lowered the risk of the disease returning when compared with standard hormone therapies long considered the backbone of treatment.

10 Dec 2025

Switching APOE4 to APOE2 in adult mice reduces Alzheimer’s pathology and improves memory

Replacing APOE4 with APOE2 in adult mice rapidly reshapes brain lipids and gene expression, even after development is complete. This switch, especially when targeted to astrocytes, reduces amyloid burden, dampens gliosis, and improves associative memory despite E2-like peripheral lipid risks.

12 Nov 2025

New combination treatment overcomes resistance in ER positive breast cancer

In preclinical studies, researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, have tested a new combination therapy for hormone-resistant, estrogen receptor-positive (ER+) breast cancer and were able to shrink tumors, reduce the number of cancer stem cells and reprogram the immune environment to be less supportive of cancer growth.

6 Nov 2025

TRF1 protein depletion linked to leaner mice and altered metabolism

A new research paper was published in Volume 17, Issue 9 of Aging-US on September 17, 2025, titled "Depletion of the TRF1 telomere-binding protein leads to leaner mice with altered metabolic profiles."

27 Oct 2025

New discovery could someday help prevent breast cancer recurrence

Know someone who's been diagnosed with breast cancer? There's a good chance that person has received hormone therapy.

21 Oct 2025

New personalized therapy boosts tamoxifen effectiveness in breast cancer patients

Breast cancer is the most common cancer among women worldwide (WHO, 2023). The Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology (IKP) has now developed a new therapy in a clinical study that tailors hormone treatment for breast cancer to the individual patient.

16 Oct 2025

Targeting the glycocalyx may offer a new approach to reduce frailty in older adults

A new research paper was published in Volume 17, Issue 9 of Aging-US on August 30, 2025, titled, "Glycocalyx-targeted therapy prevents age-related muscle loss and declines in maximal exercise capacity."

14 Oct 2025

Why protein powders can secretly cause doping bans

Adulterated protein supplements can lead to unintentional doping. This review outlines detection strategies and protective measures for athletes and clinicians.

9 Oct 2025

Piezo1 identified as key trigger for tension driven skin expansion

Investigators at Johns Hopkins Medicine report new evidence that the protein Piezo1 controls skin growth by detecting when skin is stretched and then coordinating the metabolic and immune changes necessary for growth.

5 Sep 2025

Researchers identify molecular mechanism behind tamoxifen-related uterine cancer

In a preclinical study, researchers found tamoxifen encourages uterine cell growth; the findings could change how some breast cancers are treated in the future.

22 Aug 2025

GIPR signaling opens brain’s gate for GLP-1 weight-loss therapy

A Cell Metabolism study reveals that GIPR signaling in oligodendrocytes enhances brain access and weight-loss efficacy of GLP-1R agonists by increasing vascular permeability and targeting appetite-regulating neurons. This mechanism may explain why GIPR/GLP-1R co-agonists outperform single-agent therapies.

14 Aug 2025

HOXB13 emerges as a context-dependent regulator in cancer biology

HOXB13, a B-class homeobox transcription factor, sits at the hub of developmental gene networks yet has emerged as a double-edged sword in human cancer.

5 Aug 2025